2026-06-14T03:28:48Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/74352024-09-27T10:44:29Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Heinrich, Daniel author Bektic, Jasmin author Bergman, Andries M author Caffo, Orazio author Cathomas, Richard author Chi, Kim N author Daugaard, Gedske author Keizman, Daniel author Kindblom, Jon author Kramer, Gero author Olmos, David author Omlin, Aurelius author Sridhar, Srikala S author Tucci, Marcello author van Oort, Inge author Nilsson, Sten author 2017-09-06 Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for patients treated with radium-223 and best standard of care (BSoC) when compared with placebo and BSoC in the ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial. At that time, docetaxel was the standard first-line choice for patients with metastatic CRPC (mCRPC). Since then, the treatment landscape has changed dramatically with new hormonal agents (abiraterone and enzalutamide) considered to be the first-line choice for many patients. The optimal patient profile for radium-223 in the modern setting, and its best use either in sequence or in combination with other approved agents are unclear, with few definitive guidelines available. This article reports on the views of a group of urologists and medical oncologists experienced in treating patients with mCRPC with radium-223 in routine clinical practice. The aim is to provide an overview of the current use of radium-223 in the treatment of patients with mCRPC, and to discuss best practices for patient selection and on-treatment monitoring. Where agreement was reached, guidance on the optimal use of radium-223 is provided. Clin Genitourin Cancer. 2017. pii: S1558-7673(17)30275-6 10.1016/j.clgc.2017.08.020 1938-0682 15587673 Clinical genitourinary cancer 29079165 http://hdl.handle.net/20.500.12105/7435 Bone metastases Patient selection Targeted alpha therapy Treatment monitoring Treatment sequence The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer